Parabacteroides distasonis promotes CXCL9 secretion of tumor-associated macrophages and enhances CD8+T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in non-small cell lung cancer mice

被引:0
|
作者
Zhijun Fan [1 ]
Zheng Yi [1 ]
Sheng Li [2 ]
Junjun He [2 ]
机构
[1] Department of Cardiothoracic Surgery, The People’s Hospital of Liuyang, Changsha
[2] Department of Gastrointestinal Surgery, The Central Hospital of Shaoyang, Shaoyang
关键词
CXCL9; Non-small cell lung cancer; Parabacteroides distasonis; PD-1; Tumor-associated macrophages;
D O I
10.1186/s12896-025-00963-9
中图分类号
学科分类号
摘要
Background: Parabacteroides distasonis (P. distasonis) could regulate inflammatory markers, promote intestinal barrier integrity, and block tumor formation in colon. However, the regulatory effect of P. distasonis on non-small cell lung cancer (NSCLC) remains unknown. This study aimed to investigate the regulatory effect of P. distasonis on NSCLC and its impact on tumor immunity. Methods: We first established a mouse model of Lewis lung cancer, and administered P. distasonis and intrabitoneal injection of anti-mouse PD-1 monoclonal antibody to assess the impact of P. distasonis on tumor immunity, and mouse intestinal barrier. Then, we explored the effect of P. distasonis on CD8+T cells and CXCL9 secretion mediated by tumor-associated macrophages (TAM). We used the TLR1/2 complex inhibitor CPT22 to evaluate its effect on macrophage activation. Finally, we explored the effect of P. distasonis on CD8+T cells and CXCL9 secreted by TAM in vivo. Results: In vivo, P. distasonis enhanced anti-tumor effects of anti-PD-1 in NSCLC mice, improved intestinal barrier integrity, recruited macrophages, and promoted M1 polarization. In vitro, CD86 and iNOS levels in BMDM were elevated and CD206 and Arg1 levels were suppressed in membrane fraction of P. distasonis (PdMb) group in comparison to Control group. With additional CPT22 pre-treatment, the levels of CD86 and iNOS in BMDM were reduced, and the levels of CD206 and Arg1 were increased. Compared to PBS group, P. distasonis group exhibited higher proportion of CD8+T cells in tumor tissues, along with increased positive proportion of GZMB and IFN-γ in CD8+T cells. Additionally, in comparison to Control group, PdMb group showed an elevated proportion of GZMB+T and IFN-γ+T cells within CD8+T cells, and secretion of IFN-γ, TNF-α, perforin, and GZMB in CD8+T cell supernatant increased. Moreover, the proportion of CXCL9+F4/80+ macrophages in tumor tissues was higher in P. distasonis group compared to PBS group. In comparison to Control group, CXCL9 protein level in BMDM and CXCL9 secretion level in BMDM supernatant were increased in PdMb group. Finally, P. distasonis enhanced CD8+T cell activity by secreting CXCL9 from macrophages in vivo. Conclusions: P. distasonis promoted CXCL9 secretion of TAM and enhanced CD8+T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in NSCLC mice. © The Author(s) 2025.
引用
收藏
相关论文
共 35 条
  • [21] Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy
    He, Li-na
    Zhang, Xuanye
    Li, Haifeng
    Chen, Tao
    Chen, Chen
    Zhou, Yixin
    Lin, Zuan
    Du, Wei
    Fang, Wenfeng
    Yang, Yunpeng
    Huang, Yan
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [22] TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8+ T cell priming
    Lee, Junseok
    Im, Keon-Il
    Gil, Sojin
    Na, Hyemin
    Min, Gi-June
    Kim, Nayoun
    Cho, Seok-Goo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (06)
  • [23] A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer
    Huhe, Muren
    Lou, Jiaxin
    Zhu, Yumeng
    Zhao, Yu
    Shi, Ying
    Wang, Bo
    Sun, Xiuxuan
    Zhang, Xiaoqin
    Zhang, Yang
    Chen, Zhi-Nan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 513 (04) : 1083 - 1091
  • [24] 13-Methyl-palmatrubine shows an anti-tumor role in non-small cell lung cancer via shifting M2 to M1 polarization of tumor macrophages
    Wu, Zhihui
    Zhou, Juan
    Chen, Fangwei
    Yu, Jing
    Li, Hui
    Li, Qingfeng
    Li, Wencan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 104
  • [25] Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo
    Wu, Jianzhang
    Ji, Jiansong
    Weng, Bixia
    Qiu, Peihong
    Kanchana, Karvannan
    Wei, Tao
    Wang, Yi
    Cai, Yuepiao
    Li, Xiaokun
    Liang, Guang
    ONCOTARGET, 2014, 5 (12) : 4543 - 4553
  • [26] Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non-Small Cell Lung Cancer
    Lee, Sang Hoon
    Kim, Eun Young
    Han, Jung Min
    Han, Gyoonhee
    Chang, Yoon Soo
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 851 - 864
  • [27] EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer
    Huang, Huayan
    Zhu, Xiaokuan
    Yu, Yongfeng
    Li, Ziming
    Yang, Yi
    Xia, Liliang
    Lu, Shun
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [28] Circulating tumor cells counts are associated with CD8+T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy A retrospective study
    Liu, Qingyun
    Zhao, Chaoren
    Jiang, Penghui
    Liu, Dawei
    MEDICINE, 2021, 100 (29)
  • [29] Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Nojima, Yuji
    Shimizu, Katsuhiko
    Saisho, Shinsuke
    Maeda, Ai
    Kurosaki, Takeshi
    Kurose, Koji
    Oga, Toru
    Oka, Mikio
    Nakata, Masao
    ANTICANCER RESEARCH, 2021, 41 (11) : 5469 - 5475
  • [30] ASSOCIATION OF TUMOR PD-L1 EXPRESSION AND IMMUNE BIOMARKERS WITH CLINICAL ACTIVITY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538)
    Antonia, Scott J.
    Grosso, Joseph F.
    Horak, Christine E.
    Harbison, Christopher T.
    Kurland, John F.
    Inzunza, H. David
    Gupta, Ashok
    Sankar, Vindira
    Park, Jong-Soon
    Jure-Kunkel, Maria
    Novotny, James
    Cogswell, John
    Zhang, Xiaoling
    Phillips, Therese
    Simmons, Pauline
    Simon, Jason
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S907 - S908